Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This study will carry out to assess the efficacy of GB-0998 (intravenous
immunoglobulin;400mg/kg/day for five days) in the treatment of the Guillain-Barré Syndrome
based on the changes in Hughes Functional Grade (FG) as primary endpoint, and in addition, to
assess the safety of GB-0998.